G1 Therapeutics, Inc. GTHX
Set alert
7.16 0.00 0.00%
As of Sep 17, 3:56 PM ET
7.14 Day range 7.16
52-week range unavailable
- Open
- 7.15
- Prev close
- 7.16
- Mkt cap
- 377.22M
- Vol
- 1.10M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.14
- High
- 7.16
- Forward P/E
- 0.00
- Beta
- 1.68
- Short ratio
- 1.01
- Inst. own
- 54.62%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 6, 2024
- 50-d avg
- 5.84
- 200-d avg
- 4.10
- 1y target
- 7.15
2Y chart
Events in this range
- Aug 1, 2023Rating: EF Hutton · — → Buy
- Aug 1, 2023Rating: Needham · Buy → Buy
- Aug 2, 2023Earnings: —; estimate -0.17; surprise —%
- Aug 2, 2023Rating: Wedbush · Outperform → Outperform
- Aug 2, 2023Rating: HC Wainwright & Co. · Buy → Buy
- Oct 5, 2023Downgrade: JP Morgan · Neutral → Underweight
- Nov 1, 2023Earnings: —; estimate -0.31; surprise —%
- Feb 28, 2024Earnings: —; estimate -0.27; surprise —%
- May 1, 2024Earnings: —; estimate -0.19; surprise —%
- Aug 8, 2024Earnings: —; estimate -0.17; surprise —%
Signals (95)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Aug 23, 2024 | 2 years ago |
| RSI: Overbought | Aug 7, 2024 | 2 years ago |
| RSI: Overbought | Jul 31, 2024 | 2 years ago |
| RSI: Overbought | Jul 25, 2024 | 2 years ago |
| RSI: Overbought | Jul 18, 2024 | 2 years ago |
| SMA: Bullish | Jul 16, 2024 | 2 years ago |
| SMA: Bullish | Jul 12, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 1, 2024 | 2 years ago |
| SMA: Bearish | Jun 14, 2024 | 2 years ago |
| RSI: Oversold | Jun 14, 2024 | 2 years ago |
| SMA: Bullish | Jun 13, 2024 | 2 years ago |
| SMA: Bearish | Jun 11, 2024 | 2 years ago |
| RSI: Oversold | May 29, 2024 | 2 years ago |
| SMA: Bearish | May 23, 2024 | 2 years ago |
| MACD: Sell Signal | May 22, 2024 | 2 years ago |
| MACD: Buy Signal | May 6, 2024 | 2 years ago |
| SMA: Bearish | Apr 29, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 15, 2024 | 2 years ago |
| RSI: Overbought | Apr 9, 2024 | 2 years ago |
| RSI: Overbought | Apr 3, 2024 | 2 years ago |
| SMA: Bullish | Mar 20, 2024 | 2 years ago |
| SMA: Bearish | Mar 14, 2024 | 2 years ago |
| SMA: Bullish | Mar 13, 2024 | 2 years ago |
| SMA: Bearish | Mar 12, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 29, 2024 | 2 years ago |
| SMA: Bullish | Feb 28, 2024 | 2 years ago |
| SMA: Bullish | Feb 27, 2024 | 2 years ago |
| SMA: Bearish | Feb 20, 2024 | 2 years ago |
| SMA: Bullish | Feb 15, 2024 | 2 years ago |
| SMA: Bearish | Feb 13, 2024 | 2 years ago |
| SMA: Bearish | Feb 13, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 13, 2024 | 2 years ago |
| RSI: Overbought | Jan 29, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 22, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 11, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 10, 2024 | 2 years ago |
| MACD: Sell Signal | Dec 20, 2023 | 2 years ago |
| SMA: Bullish | Dec 6, 2023 | 2 years ago |
| RSI: Overbought | Dec 6, 2023 | 2 years ago |
| RSI: Overbought | Dec 1, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 14, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 10, 2023 | 2 years ago |
| SMA: Bearish | Nov 9, 2023 | 2 years ago |
| SMA: Bullish | Nov 2, 2023 | 3 years ago |
| SMA: Bearish | Nov 1, 2023 | 3 years ago |
| SMA: Bullish | Oct 27, 2023 | 3 years ago |
| RSI: Oversold | Oct 4, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 29, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 19, 2023 | 3 years ago |
| RSI: Oversold | Sep 15, 2023 | 3 years ago |
| RSI: Oversold | Sep 13, 2023 | 3 years ago |
| RSI: Oversold | Aug 30, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 29, 2023 | 3 years ago |
| RSI: Oversold | Aug 11, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 1, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 31, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 27, 2023 | 3 years ago |
| SMA: Bearish | Jul 20, 2023 | 3 years ago |
| SMA: Bullish | Jul 19, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 17, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 21, 2023 | 3 years ago |
| SMA: Bearish | Jun 20, 2023 | 3 years ago |
| SMA: Bullish | Jun 13, 2023 | 3 years ago |
| SMA: Bearish | Jun 12, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 6, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| SMA: Bearish | May 25, 2023 | 3 years ago |
| MACD: Sell Signal | May 25, 2023 | 3 years ago |
| SMA: Bullish | May 19, 2023 | 3 years ago |
| MACD: Buy Signal | May 19, 2023 | 3 years ago |
| MACD: Sell Signal | May 17, 2023 | 3 years ago |
| SMA: Bearish | May 16, 2023 | 3 years ago |
| SMA: Bullish | May 15, 2023 | 3 years ago |
| SMA: Bullish | May 9, 2023 | 3 years ago |
| SMA: Bearish | May 8, 2023 | 3 years ago |
| SMA: Bullish | May 3, 2023 | 3 years ago |
| SMA: Bearish | May 2, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| RSI: Oversold | Mar 23, 2023 | 3 years ago |
| RSI: Oversold | Mar 9, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 7, 2023 | 3 years ago |
| RSI: Oversold | Feb 24, 2023 | 3 years ago |
| SMA: Bearish | Feb 13, 2023 | 3 years ago |
| RSI: Oversold | Feb 13, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 10, 2023 | 3 years ago |
| RSI: Overbought | Jan 31, 2023 | 3 years ago |
| SMA: Bullish | Jan 20, 2023 | 3 years ago |
| SMA: Bearish | Jan 18, 2023 | 3 years ago |
| SMA: Bullish | Jan 17, 2023 | 3 years ago |
| MACD: Buy Signal | Dec 2, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 18, 2022 | 3 years ago |
| RSI: Oversold | Nov 18, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 15, 2022 | 3 years ago |
| RSI: Oversold | Nov 2, 2022 | 4 years ago |
Key statistics
- Market cap
- 377.22M
- Enterprise value
- 364.46M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 6.48
- Price / book
- 15.31
- EPS (TTM)
- -0.86
- Beta
- 1.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -76.93%
- Revenue (TTM)
- 58.20M
- Revenue growth
- -61.00%
- Free cash flow
- -19.83M
- Total cash
- 60.73M
- Total debt
- 47.96M
- Return on equity
- -109.01%
- Shares outstanding
- 52.76M
- Short % of float
- 6.52%
- 50-day average
- 5.84
- 200-day average
- 4.10
Analyst view
Consensus: hold
Hold
Price target (mean) 7.15
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 6, 2024
Expected Nov 6, 2024. Consensus EPS estimate -0.09.
Financials — quick view
GTHX Revenue — quarterly 16.55M
GTHX Net income — quarterly -5.47M
GTHX EPS — quarterly -0.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.12 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.17 | — | — | — |
| May 1, 2024 | Mar 1, 2024 | -0.19 | — | — | — |
| Feb 28, 2024 | Dec 1, 2023 | -0.27 | — | — | — |
| Nov 1, 2023 | Sep 1, 2023 | -0.31 | — | — | — |
| Aug 2, 2023 | Jun 1, 2023 | -0.17 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2023 | JP Morgan | down | Neutral | Underweight |
| Aug 2, 2023 | Wedbush | reit | Outperform | Outperform |
| Aug 2, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 1, 2023 | EF Hutton | reit | — | Buy |
| Aug 1, 2023 | Needham | main | Buy | Buy |
| Jun 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About G1 Therapeutics, Inc.
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- g1therapeutics.com
News
- Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
- GTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc.
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
- G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
- G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
- Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
- Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
- Pharmacosmos Group to Acquire G1 Therapeutics
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
Your note
Sign in to keep a note on GTHX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AVAGLIANO MARK | Officer | Stock Award(Grant) | Sep 17, 2024 | 0 |
| BAILEY JOHN E JR | Chief Executive Officer | Stock Award(Grant) | Sep 17, 2024 | 0 |
| MALIK RAJESH K. | Officer | Stock Award(Grant) | Sep 17, 2024 | 0 |
| MUIR GLENN P | Director | Stock Award(Grant) | Jun 12, 2024 | 205,358 |
| MURDOCK TERRY L. | Chief Operating Officer | Stock Award(Grant) | Sep 17, 2024 | 0 |
| NICHOLSON GARRY A | Director | Stock Award(Grant) | Jun 12, 2024 | 34,389 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fisher Asset Management, LLC | 4.91% | 2,543,006 | 6.33M | Jun 29, 2023 |
| JP Morgan Chase & Company | 4.09% | 2,115,873 | 5.27M | Jun 29, 2023 |
| Vanguard Group Inc | 3.77% | 1,950,068 | 4.86M | Jun 29, 2023 |
| Blackrock Inc. | 2.29% | 1,185,645 | 2.95M | Jun 29, 2023 |
| Raymond James & Associates, Inc. | 1.53% | 792,114 | 1.97M | Jun 29, 2023 |
| Shaw D.E. & Co., Inc. | 1.19% | 616,503 | 1.54M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.50% | 1,295,502 | 3.23M | Jun 29, 2023 |
| JP Morgan Small Cap Growth Fund | 2.38% | 1,233,467 | 3.07M | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.13% | 583,255 | 1.45M | Jun 29, 2023 |
| iShares NASDAQ Biotechnology ETF | 0.58% | 302,415 | 505.03K | Aug 30, 2023 |
| Fidelity Extended Market Index Fund | 0.47% | 242,045 | 614.79K | May 30, 2023 |
| Tekla Life Sciences Investors | 0.43% | 223,377 | 556.21K | Jun 29, 2023 |